NDA 022180 · Azurity
Feraheme
Ferumoxytol · Intravenous · Parenteral Iron Replacement
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jun 30, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
97
20 Phase 3, 15 recruiting
FAERS reports
1,942
1,190 serious, 131 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK FOR SERIOUS HYPERSENSITIVITY/ANAPHYLAXIS REACTIONS Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme. Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest. • Only administer Feraheme as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions [see Warnings and Precautions ( 5.1 )] . • Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following Feraheme infusion including monitoring of blood pressure and pulse during and after Feraheme administration [see Warnings and Precautions ( 5.1 )]. • Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated [see...
What it is approved for
From the label in effect May 31, 2026.
Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: • who have intolerance to oral iron or have had unsatisfactory response to oral iron or • who have chronic kidney disease (CKD). Feraheme is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients: • who have intolerance to oral iron or have had unsatisfactory response to oral iron ( 1 ) or • who have chronic kidney disease (CKD). ( 1 )
Mechanism: Feraheme consists of a superparamagnetic iron oxide that is coated with a carbohydrate shell, which helps to isolate the bioactive iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen and bone marrow. The iron is released from the iron-carbohydrate complex within vesicles in the macrophages. Iron then either enters the intracellular storage iron pool (e.g., ferritin) or is transferred to plasma transferrin for transport to erythroid precursor cells for incorporation into hemoglobin.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 2, 2018 Supplement 9 · Efficacy LabelLetter
- Jun 30, 2009 Original approval · Type 2 - New Active Ingredient LabelReviewSummary Review
1 products under this application
- FERAHEME · FERUMOXYTOL EQ 510MG IRON/17ML (EQ 30MG IRON/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ferumoxytol" as an intervention, any sponsor and status, largest first.
- A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)Pivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT02694978 · 2,014 participants · Start Feb 29, 2016 · Primary completion Jan 16, 2017
Drug: Ferumoxytol; FCM · For: Iron Deficiency Anemia
Sites: Huntsville, Alabama; Tucson, Arizona; Anaheim, California · 127 sites in all
- A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency AnemiaPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01114139 · 812 participants · Start Jun 19, 2010 · Primary completion Feb 27, 2012
Drug: Ferumoxytol · For: Iron Deficiency Anemia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 182 sites in all
- A Crossover Safety Study of Ferumoxytol Versus PlaceboPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT00255450 · 750 participants · Start Jan 2005
Drug: ferumoxytol or placebo · For: Anemia
Sites: Mobile, Alabama; Phoenix, Arizona; Mountain View, California · 41 sites in all
- A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency AnemiaPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01114217 · 634 participants · Start Jul 27, 2010 · Primary completion Sep 24, 2012
Drug: Ferumoxytol · For: Iron Deficiency Anemia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 140 sites in all
- A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency AnemiaPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01114204 · 605 participants · Start Aug 10, 2010 · Primary completion Nov 9, 2011
Drug: Ferumoxytol; Iron Sucrose · For: Iron Deficiency Anemia
Sites: Adelaide, Australia; Ballarat, Australia; Concord, Australia · 96 sites in all
- Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT00255437 · 304 participants · Start Jun 2004
Drug: ferumoxytol or oral iron · For: Anemia
Sites: Phoenix, Arizona; Tempe, Arizona; New Haven, Connecticut · 13 sites in all
- Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease PatientsPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT00255424 · 304 participants · Start May 2004
Drug: ferumoxytol or oral iron · For: Anemia
Sites: Encino, California; Riverside, California; Tarzana, California · 19 sites in all
- Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on HemodialysisPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01227616 · 296 participants · Start Aug 2013 · Primary completion Feb 2016
Drug: Ferumoxytol; Iron Sucrose · For: Iron Deficiency Anemia Treatment; Chronic Kidney Disease(CKD)
Sites: Pine Bluff, Arkansas; Azusa, California; Beverly Hills, California · 43 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea468
- nausea242
- flushing230
- back pain211
- infusion related reaction211
- hypotension205
- anaphylactic reaction185
- dizziness183
- chest discomfort175
- hypersensitivity155
- chest pain139
- unresponsive to stimuli139
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 15 |
| 2010 | 199 |
| 2011 | 96 |
| 2012 | 75 |
| 2013 | 45 |
| 2014 | 65 |
| 2015 | 75 |
| 2016 | 101 |
| 2017 | 119 |
| 2018 | 150 |
| 2019 | 246 |
| 2020 | 176 |
| 2021 | 154 |
| 2022 | 103 |
| 2023 | 85 |
| 2024 | 86 |
| 2025 | 80 |
| 2026 | 72 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect and safety of intravenous iron compared to oral iron for treatment of iron deficiency anaemia in pregnancy.
Nicholson L, Axon E, Daru J, et al. · Cochrane Database Syst Rev 2024 · Systematic Review
- A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia.
Short V, Allen R, Earley CJ, et al. · Am J Hematol 2024 · Randomized Controlled Trial, Comparative Study
- Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
Shepshelovich D, Rozen-Zvi B, Avni T, et al. · Am J Kidney Dis 2016 · Comparative Study, Meta-Analysis
- Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.
Ravi H, Arias-Lorza AM, Costello JR, et al. · Radiol Imaging Cancer 2023 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Ferumoxytol for treating iron deficiency anemia in CKD.
Spinowitz BS, Kausz AT, Baptista J, et al. · J Am Soc Nephrol 2008 · Clinical Trial, Phase III, Randomized Controlled Trial
- Can the biomolecular corona induce an allergic reaction?-A proof-of-concept study.
Muehe A, Nejadnik H, Muehe H, et al. · Biointerphases 2021 · Clinical Trial, Research Support, N.I.H., Extramural
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.